Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion

Linda Stein Gold; Mark Lebwohl; Neal  Bhatia; Douglas DiRuggiero; Abby Jacobson; Radhakrishnan Pillai

doi:10.25251/skin.4.supp.79

Linda Stein Gold

Henry Ford Hospital, Detroit, MI

Mark Lebwohl

Icahn School of Medicine at Mount Sinai, New York, NY

Neal Bhatia

Therapeutics Clinical Research, San Diego, CA

Douglas DiRuggiero

Skin Cancer & Cosmetic Dermatology, Rome, Georgia

Abby Jacobson

Ortho Dermatologics*, Bridgewater, NJ

Radhakrishnan Pillai

Bausch Health US, LLC*, Petaluma, CA

Keywords

Psoriasis, Plaque Psoriasis, Topical, Corticosteroid, Halobetasol, Retinoid, Tazarotene, Cessation, Treatment Success

Abstract

Abstract not available.

References

1. Nestle FO, et al. N Engl J Med. 2009;361(5):496-509.

2. Benhadou F, et al. Dermatology. 2019;235(2):91-100.

3. Tanghetti E, et al. J Dermatolog Treat. 2019:1‑8.

4. Chandraratna RA. J Am Acad Dermatol. 1997;37(2 Pt 3):S12-17.

5. Duvic M, et al. J Am Acad Dermatol. 1997;37(2 Pt 3):S18-24.

6. Tanghetti E, et al. J Drugs Dermatol. 2018;17(12):1280-1287.

Poster PDF

Published

Oct 27, 2020

DOI https://doi.org/10.25251/skin.4.supp.79

How to Cite

Stein Gold, L., Lebwohl, M., Bhatia, N. ., DiRuggiero, D., Jacobson, A., & Pillai, R. (2020). Long-Term Management of Moderate-to-Severe Plaque Psoriasis: Maintenance of Treatment Success Following Cessation of Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion. SKIN The Journal of Cutaneous Medicine, 4(6), s79. https://doi.org/10.25251/skin.4.supp.79

Issue

Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)

Section

Poster Presentations from FC20 Clinical Dermatology Conference®: Psoriasis

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by the following user license:

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Author Biographies

Abby Jacobson, Ortho Dermatologics*, Bridgewater, NJ

*Bausch Health US, LLC is an affiliate of Bausch Health Companies Inc.

Radhakrishnan Pillai, Bausch Health US, LLC*, Petaluma, CA

Ortho Dermatologics is a division of Bausch Health US, LLC

Most read articles by the same author(s)

Craig Leonardi, Linda Stein Gold, Edward Lain, Andrea Neimann, Abby Jacobson, Halobetasol 0.01%/Tazarotene 0.045% (HP/TAZ) Lotion for the Treatment of Plaque Psoriasis in Patients With 3-5% Body Surface Area , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 6 (2020): November Issue & Poster Presentations (FC20 Dermatology Conference®)
Neil J. Korman, Thierry Passeron, Kenneth B. Gordon, Yukari Okubo, Jerry Bagel, Howard Sofen, Richard B. Warren, Neal Bhatia, Lynda Spelman, Kevin Winthrop, Lauren Hippeli, Renata M. Kisa, Subhashis Banerjee, Diamant Thaçi, Deucravacitinib in plaque psoriasis: 2-year laboratory results from the phase 3 POETYK PSO program , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Lawrence F Eichenfield, Boni Elewski, Jeffrey L Sugarman, Ted Rosen, Aditya Gupta, Wendy Cantrell, Radhakrishnan Pillai, Abby Jacobson, Safety, Pharmacokinetics, and Efficacy of Efinaconazole 10% Topical Solution for the Treatment of Onychomycosis in Pediatric Patients , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 5 (2020): September Issue & Poster Presentations (FCPANP20® Dermatology Conference)
Neal Bhatia, April W Armstrong, Todd Schlesinger, Leon Kircik, Brian Berman, Mark Lebwohl, Darrell Rigel, Vishal A Patel, James Del Rosso, Ayman Grada, Siva Narayanan, Ismail Kasujee, An Expert Panel Questionnaire for Assessing Patient-Reported and Clinician-Reported Outcomes in Actinic Keratosis , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Athanasios Tsianakas, Neal Bhatia, Shanavas Alikunju, Anirudh Gautam, Srinivas Shenoy, Preeti Singh, Srinivas Sidgiddi, DFD-29, a low dose oral minocycline, demonstrates superior efficacy as compared to placebo and Oraycea ® Capsules (doxycycline HCl) in subjects with papulopustular rosacea , SKIN The Journal of Cutaneous Medicine: Vol. 3 (2019): Supplemental Issue: Scientific Posters Presented at 2019 Fall Clinical Dermatology Conference®-Las Vegas
Fran E Cook-Bolden, MD, Linda Stein Gold, MD, Hilary Baldwin, MD, Valerie Callender, MD, Andrew F Alexis, MD, MPH, Neal Bhatia, MD, Joshua A Zeichner, MD, Emil A Tanghetti, MD, Eric Guenin, PharmD, PhD, MPH, Safety of Tazarotene 0.045% Lotion and Hyperpigmentation Improvements in Black Participants With Moderate-to-Severe Acne , SKIN The Journal of Cutaneous Medicine: Vol. 7 No. 4 (2023): July Issue & Posters from FCPANP 23
Sarina Singer, Nahla Shihab, Mark Lebwohl, Cyclosporine for Severe Drug Eruption in a Psoriasis Patient , SKIN The Journal of Cutaneous Medicine: Vol. 4 No. 4 (2020)
Leon Kircik, Lawrence Green, Joshua Zeichner, Javier Alonso-Llamazares, Abby Jacobson, Long-term Outcomes of Fixed-Combination Halobetasol Propionate and Tazarotene Lotion Stratified by Baseline Signs and Symptoms of Psoriasis , SKIN The Journal of Cutaneous Medicine: Vol. 5 No. 6 (2021): November Issue & Poster Presentations (FC21 Dermatology Conference®)
Linda Stein Gold, Mark Lebwohl, Robert Bissonnette, Bruce Strober, Anna M Tallman, Philip M Brown, Stephen C Piscitelli, David S Rubenstein, Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Pooled Efficacy from Three Phase 3 Trials , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®
Laura K Ferris, April W Armstrong, James Del Rosso, Zoe D Draelos, Melinda Gooderham, Mark Lebwohl, Kim A Papp, Jennifer Soung, Linda Stein Gold, David Krupa, Robert C Higham, Patrick Burnett, David R Berk, Efficacy and Tolerability of Roflumilast Cream 0.3% in Patients With Chronic Plaque Psoriasis Involvement on the Face, Intertriginous, or Genital Areas: Pooled Results From Phase 3 Trials (DERMIS-1 and DERMIS-2) , SKIN The Journal of Cutaneous Medicine: Vol. 6 No. 6 (2022): November Issue & Poster Presentations from FC22 Dermatology Conference®

<< < 7 8 9 10 11 12 13 14 15 16 > >>

Main Article Content